Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the central nervous system (CNS) in the United States. More Details
Excellent balance sheet with high growth potential.
Share Price & News
How has Intra-Cellular Therapies's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ITCI is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: ITCI's weekly volatility has decreased from 13% to 7% over the past year.
7 Day Return
1 Year Return
Return vs Industry: ITCI exceeded the US Pharmaceuticals industry which returned 16.4% over the past year.
Return vs Market: ITCI exceeded the US Market which returned 39.7% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Intra-Cellular Therapies's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 days ago | Simply Wall StWe Think The Compensation For Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) CEO Looks About Right
2 weeks ago | Simply Wall StIf You Had Bought Intra-Cellular Therapies (NASDAQ:ITCI) Stock A Year Ago, You Could Pocket A 89% Gain Today
1 month ago | Simply Wall StShould You Review Recent Insider Transactions At Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)?
Is Intra-Cellular Therapies undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ITCI ($43) is trading below our estimate of fair value ($574.51)
Significantly Below Fair Value: ITCI is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ITCI is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.
PE vs Market: ITCI is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ITCI's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ITCI is overvalued based on its PB Ratio (5.7x) compared to the US Pharmaceuticals industry average (3.3x).
How is Intra-Cellular Therapies forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ITCI is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: ITCI is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ITCI's is expected to become profitable in the next 3 years.
Revenue vs Market: ITCI's revenue (51.4% per year) is forecast to grow faster than the US market (9.3% per year).
High Growth Revenue: ITCI's revenue (51.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ITCI's Return on Equity is forecast to be low in 3 years time (14.6%).
How has Intra-Cellular Therapies performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ITCI is currently unprofitable.
Growing Profit Margin: ITCI is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ITCI is unprofitable, and losses have increased over the past 5 years at a rate of 15.8% per year.
Accelerating Growth: Unable to compare ITCI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ITCI is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (0.3%).
Return on Equity
High ROE: ITCI has a negative Return on Equity (-37.95%), as it is currently unprofitable.
How is Intra-Cellular Therapies's financial position?
Financial Position Analysis
Short Term Liabilities: ITCI's short term assets ($649.1M) exceed its short term liabilities ($39.7M).
Long Term Liabilities: ITCI's short term assets ($649.1M) exceed its long term liabilities ($22.6M).
Debt to Equity History and Analysis
Debt Level: ITCI is debt free.
Reducing Debt: ITCI had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ITCI has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if ITCI has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Intra-Cellular Therapies's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ITCI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ITCI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ITCI's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ITCI's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ITCI's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Sharon Mates (67 yo)
Dr. Sharon Mates, Ph.D., co-founded Intra-Cellular Therapies, Inc. (a/k/a ITI) in May 2002 and has been its Chairman, President and Chief Executive Officer since June 2002. Earlier in her career, Dr. Mates...
CEO Compensation Analysis
Compensation vs Market: Sharon's total compensation ($USD5.48M) is about average for companies of similar size in the US market ($USD5.24M).
Compensation vs Earnings: Sharon's compensation has increased whilst the company is unprofitable.
Experienced Management: ITCI's management team is considered experienced (4.2 years average tenure).
Experienced Board: ITCI's board of directors are considered experienced (7.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 22.2%.
Intra-Cellular Therapies, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Intra-Cellular Therapies, Inc.
- Ticker: ITCI
- Exchange: NasdaqGS
- Founded: NaN
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$3.505b
- Shares outstanding: 81.20m
- Website: https://www.intracellulartherapies.com
Number of Employees
- Intra-Cellular Therapies, Inc.
- 430 East 29th Street
- Suite 900
- New York
- New York
- United States
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the central nervous system (CNS) in t...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/06/18 02:56|
|End of Day Share Price||2021/06/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.